21 st Century Cures Act: An Act of Cure or Diagnosis?

Rejuvenation ResearchVol. 18, No. 4 Guest Editorial21st Century Cures Act: An Act of Cure or Diagnosis?David A. Brindley, Zeeshaan Arshad, Dee Luo, Sue Dopson, Georg Hollander, Stephen Frost, Chas Bountra, and James A. SmithDavid A. BrindleySaid Business School, University of Oxford, Oxford, United Kingdom.Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.The Oxford–UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), The University of Oxford, United Kingdom.Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, United Kingdom.Harvard Stem Cell Institute, Cambridge, Massachusetts.USCF–Stanford Center of Excellence in Regulatory Science and Innovation (CERSI), San Francisco, California.Search for more papers by this author, Zeeshaan ArshadStructural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.School of Medicine, University of St. Andrews, St. Andrews, United Kingdom.Search for more papers by this author, Dee LuoSENS Research Foundation, Mountain View, California.College of Arts and Sciences, Department of Biological Basis of Bahavior, University of Pennsylvania, Pennsylvania.Search for more papers by this author, Sue DopsonSaid Business School, University of Oxford, Oxford, United Kingdom.Search for more papers by this author, Georg HollanderWeatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom.Search for more papers by this author, Stephen FrostFrost Included Ltd., London, United KingdomWomen and Public Policy Program, Harvard Kennedy School, Harvard University Cambridge, Massachusetts.Search for more papers by this author, Chas BountraStructural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.Search for more papers by this author, and James A. SmithNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.The Oxford–UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), The University of Oxford, United Kingdom.Search for more papers by this authorPublished Online:20 Aug 2015https://doi.org/10.1089/rej.2015.1757AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byNIH funding trends for neurosurgeon-scientists from 1993–2017: Biomedical workforce implications for neurooncology7 July 2021 | Journal of Neuro-Oncology, Vol. 154, No. 1Therapeutic Drug Monitoring in Pregnant PatientsTherapeutic Drug Monitoring, Vol. 42, No. 2Regulatory barriers to the advancement of precision medicine29 April 2016 | Expert Review of Precision Medicine and Drug Development, Vol. 1, No. 3A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics28 January 2016 | Frontiers in Genetics, Vol. 6The 21st Century Cures Act: can the regulatory framework survive the “cures”?Cadernos de Saúde Pública, Vol. 31, No. 9 Volume 18Issue 4Aug 2015 InformationCopyright 2015, Mary Ann Liebert, Inc.To cite this article:David A. Brindley, Zeeshaan Arshad, Dee Luo, Sue Dopson, Georg Hollander, Stephen Frost, Chas Bountra, and James A. Smith.21st Century Cures Act: An Act of Cure or Diagnosis?.Rejuvenation Research.Aug 2015.295-298.http://doi.org/10.1089/rej.2015.1757Published in Volume: 18 Issue 4: August 20, 2015PDF download